



MATERIAL SAFETY DATA SHEET

Product Name: Ceftriaxone for Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Distributor Name Hospira, Inc.
And Address 275 North Field Drive
Lake Forest, Illinois 60045
USA

Emergency Telephone CHEMTREC: 800 424-9300
Hospira, Inc. 224 212-2055

Manufacturer Name Sandoz GmbH
And Address Biochemiestrasse. 10
A-6250 Kundl,/ Tirol
Austria

Product Name Ceftriaxone for Injection, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Ceftriaxone sodium
Chemical Formula $C_{18}H_{16}N_8Na_2O_7S_3 \cdot 3.5H_2O$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Ceftriaxone sodium	100	78439-06-2	NA

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used as an antibiotic to treat infection. May cause sensitization by inhalation and skin contact. Ceftriaxone may cause severe allergic reactions.

Occupational Exposure Potential Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Workplace overexposure may include symptoms of hypersensitivity such as rash, itching, difficulty breathing, nausea, or diarrhea.

Signs and Symptoms Data on this class of compound (cephalosporins) suggest the following: allergic reaction, eye irritation, rash, itching, difficulty breathing, nausea, or anaphylactic shock.

Medical Conditions Aggravated by Exposure Hypersensitivity to penicillin or cephalosporin compounds.

Product Name: Ceftriaxone for Injection, USP

4. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable

Fire & Explosion Hazard: Powders dispersed in air and subjected to an ignition source could explode.

Extinguishing Media: Use extinguishing media appropriate for primary cause of fire.

Special Fire Fighting Procedures No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Collect spilled powder using techniques that minimize powder migration. Clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling No special handling required.

Storage No special storage required for hazard control. For product protection store at controlled room temperature of 20-25°C (68-77°F).

Special Precautions No special precautions related to hazard control.

Product Name: Ceftriaxone for Injection, USP

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines	None established.
Respiratory Protection	Respiratory protection is not needed during normal product use. Should powder inhalation be an exposure risk use of an approved respirator would be prudent practice.
Skin Protection	If contact with unprotected skin is likely, glove use is prudent practice.
Eye Protection	Eye protection is not required during expected product use conditions but may be warranted if eye contact is likely.
Engineering Controls	Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	White to yellowish crystalline powder.
Odor	Not Determined
Boiling Point	Not Determined
Freezing Point	Not Determined
Vapor Pressure	Not Determined
Vapor Density (Air=1)	Not Applicable
Evaporation Rate	Not Applicable
Bulk Density	Not Determined
Specific Gravity	Not Determined
Solubility	Water: 30 g/l, 25 degrees C
pH	6 – 8 (100g/l, 25 degrees C)

10. STABILITY AND REACTIVITY

Chemical Stability	Stable under standard use and storage conditions.
Incompatibilities	May react with strong oxidizing agents.
Hazardous Decomposition Products	May emit toxic smoke.
Hazardous Polymerization	Will not occur.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:

Ingredient(s)	Percent	Test Type	Value	Units	Species
Ceftriaxone	100	LD50	>10,000	mg/kg	Rats

LD50 is the dosage producing 50% mortality.
Product contains approximately 100% Ceftriaxone.

Mutagenicity	Not mutagenic. (Ames test)
Reproductive Effects	No effects identified.
Target Organ Effects	May cause blood system changes. Other target organs include liver and kidneys.

Product Name: Ceftriaxone for Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Available

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status Not Regulated
CERCLA Status Not Regulated
SARA Status Not Regulated
RCRA Status Not Regulated
PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator Global Occupational Toxicology
Date Prepared September 15, 2005
Date Revised October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.